Progesterone receptors – animal models and cell signalling in breast cancer: Implications for breast cancer of inclusion of progestins in hormone replacement therapies

AUTOR(ES)

Schairer, Catherine

FONTE

BioMed Central

RESUMO

Progestins are included in menopausal hormone replacement therapy to counteract the increased risk for endometrial cancer associated with estrogen replacement therapy. Studies of hormone replacement therapy and breast cancer risk and of changes in mammographic density according to different regimens of hormone replacement therapy suggest that, for the most part, estrogen–progestin replacement therapy has a more adverse effect on breast cancer risk than does estrogen replacement therapy. Many questions remain unresolved, however, including risk associated with different regimens of estrogen–progestin replacement therapy, and whether the effects vary according to tumor characteristics, such as histology, extent of disease, and hormone receptor status.

Documentos Relacionados

• Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer
• Progesterone receptors - animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer
• Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis
• Progesterone receptors - animal models and cell signaling in breast cancer: Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells
• Progesterone receptors - animal models and cell signaling in breast cancer: Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics